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Purpose: To evaluate the role of topical umbilical cord serum (TUCS) therapy in treating
corneal epithelial defects (CEDs) after diabetic vitrectomy.
Methods: In this double-masked, randomized clinical trial, we included 80 eyes of 80
patients who were candidates for vitrectomy due to proliferative diabetic retinopathy
complications. In cases of corneal edema obscuring the fundus view during surgery,
the corneal epithelium was removed using a 6-mm trephine and a blade no.15. The day
after the surgery, patients were randomly divided into two groups: (1) the TUCS group
that received 20% TUCS six times/day in addition to the conventional treatment of CED
and (2) the control group, which was prescribed artificial tears as placebo in addition to
the conventional treatment of CED. The rate of healing of CEDs was measured via two
maximum linear dimensions perpendicular to each other at the start of therapy and on
postoperative days 1–5, 7, and 12.
Results: Of 80 eyes, 40 were assigned to each treatment group. The mean times to
complete CED healing were 2.4± 0.7 and 3.8± 2.1 days in the TUCS and control groups,
respectively (P < 0.001). Persistent CED occurred in two eyes in the control group but in
no eyes in the TUCS group.
Conclusion: TUCS therapy may be safe and effective in healing CEDs after vitrectomy
in patients with diabetes.
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The removal of corneal epithelium may be
necessary to improve a surgeon’s visualization of
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fundus during vitrectomy. In diabetic patients,
abnormal postoperative healing of corneal epithe-
lial defects (CEDs) results in morbidity and prolongs
the hospitalization period. Generally, patients with
diabetes are at a high risk of developing corneal
disorders, a condition known as diabetic keratopa-
thy due to insufficient epithelial adherence to the
Bowman’s membrane. Significant recurrent corneal
erosions can occur after intraocular surgery, par-
ticularly vitrectomy, in such patients.[1, 2] Treatment
options for diabetic keratopathy are limited. Recent
studies have reported the effectiveness of topical
umbilical cord serum (TUCS) in treating ocular
surface disorders, such as neurotrophic keratitis,
dry eye syndrome, and persistent CEDs.[3–5] Sev-
eral growth factors, such as the epidermal growth
factor (EGF), acidic and basic fibroblast growth
factors (FGFs), platelet-derived growth factor, hep-
atocyte growth factor, vitamin A, transforming
growth factor-β (TGF- β), substance P, insulin-like
growth factor-1 (IGF-1), nerve growth factor (NGF),
fibronectin, and α2-macroglobulin, are present in
umbilical cord serum (UCS). Furthermore, concen-
trations of EGF, TGF-B, and NGF are several times
higher in UCS than in peripheral blood.[4, 5] We
performed this study to investigate whether TUCS
may have a beneficial role in healing CEDs after
diabetic vitrectomy.
METHODS
In this double-masked, prospective randomized
controlled clinical trial (RCT), we included all
patients with type II diabetes who underwent
deep vitrectomy because of proliferative diabetic
retinopathy (PDR) complications and had corneal
epithelial edema during surgery that prompted
removal of the corneal epithelium to improve the
media clarity. A 6-mm trephine was used to equal-
ize the basic CED size.
The exclusion criteria were a history of herpetic,
exposure, or neurotrophic keratitis, previous kera-
torefractive surgery, significant dry eye, trachoma-
tous keratopathy, immune or nutritional deficiency,
a history of autoimmune diseases, lid abnormality,
use of glaucoma eye drops or any other eye drop
after surgery (except for drops that were used
during the study), and pregnancy. Eyes with severe
lid edema after surgery were also excluded.
The study protocol was approved by the insti-
tutional review board of the Ophthalmic Research
Center of the Shahid Beheshti University of Medical
Sciences. This study was conducted according to
the Declaration of Helsinki and all participants gave
written informed consent before entering the study.
This RCT was registered at www.ClinicalTrial.gov
(NCT01168375).
Patients in the TUCS group received 20%
TUCS eye drops (diluted with preservative-
free artificial tears) six times/day in addition to
the conventional treatment (chloramphenicol
and betamethasone eye drops four times
daily and cycloplegic eye drops three
times daily). Patients in the control group
received the conventional treatment and a
placebo (preservative-free artificial tears),
without patching the eye between the drop
administrations.
Patients were followed-up on postoperative
days 1–5, 7, and 12. Corneal photography was
performed after administration of the fluorescein
dye. The longest linear diameter and the longest
vertical diameter of the CED area were measured
and multiplied to obtain the area of the equivalent
rectangle. The rate of healing of CEDs was mea-
sured at each subsequent follow-up. The umbilical
cord blood was obtained from healthy mothers
with uncomplicated cesarean section delivery after
screening for parenterally transmitted viral dis-
eases, hepatitis B and C, human immunodeficiency
virus, cytomegalovirus, and syphilis at the Royan
Institute Cord Blood Bank. Briefly, samples that
were negative for viruses and microbes were
centrifuged at 1,500 rotations/min for 5 min, and
the supernatant cells were discarded. No anticoag-
ulants were used in the procedure. Umbilical cord
serum was stored at –20.0°C in 5 ml bottles. The
maximum storage time was three months. To pre-
pare eye drops, one bottle was opened, and UCS
was diluted with preservative-free artificial tears
to achieve the 20% concentration. Samples were
then stored at 4.0°C for three days. Subsequently,
a new bottle was opened, and the old bottle was
discarded. Randomization was performed using
the random-block permutation method using a
computer-generated randomized list. Patientswere
then assigned to one of the two groups: case
or control. A random allocation sequence was
performed by a biostatistician. Details of the series
were unknown to the study investigators. All study
personnel and participants were masked to the
treatment throughout the study. TUCS and placebo
eye drops were prepared and labeled using codes
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by a non-study ward staff based on the random-
ization list provided. Only the study biostatistician
who had no contact with the study participants was
unmasked to the treatment groups.
Sample Size
In the pilot study, the standard deviations of time to
remission in the umbilical cord serum and placebo
groups were 0.8 and 2.0, respectively. To achieve
an 85% power in detecting one-day differences
between the new intervention and conventional
treatment groups with a type-I error of 5%, we
needed 40 patients in each group.
Statistical Analysis
Data are expressed as mean ± standard deviation,
median, range, percent, and 95% confidence inter-
val (CI). To evaluate differences between groups,
we used the Chi-square test, Fisher’s exact test
and t-test, whenever appropriate. Relationships
between age and duration of operation and time to
remission were evaluated using Spearman’s corre-
lation coefficient. Analyses were performed using
SPSS (version 17.0, SPSS Inc., Chicago, IL, USA). P
< 0.05 was considered statistically significant.
RESULTS
In total, 80 eyes of 80 patients (42 women [52.5%]
and 38men [47.5%]), with amean age of 58.5± 10.3
(median: 58; range: 34 to 80) years, were enrolled
in this study. Their mean basic CED size was 15.5 ±
6.5 (median: 14; range: 2 to 33) mm2 the day after
the surgery [Table 1].
As demonstrated in Table 2 and Figure 1, the rate
of improvement of CEDs was 1.3 days lesser in the
case group than in the control group (95% CI: 0.6–
2.1, P < 0.001).
There was no statistically significant difference
between men and women in the rate of improve-
ment (3.13 ± 1.74 in men vs 3.05 ± 1.73 in women, P
= 0.833) in the case and control groups (P = 0.451
and P = 0.885, respectively).
Additionally, we found no significant correlation
of the age or duration of operation with the overall
rate of improvement in either group [Table 3]. Two
cases of persistent CED occurred in the control
group, but no eyes in the TUCS group showed this
complication.
DISCUSSION
Diabetic vitrectomy typically necessitates pars
plana vitrectomy to treat complications of PDR.
Corneal epithelial edema and late corneal
decompensation can occur during vitreoretinal
surgery.[6] Intraoperative corneal epithelial
edema causes media haziness; therefore, the
surgeon may mechanically scrape the epithelium
with a blade to improve the media clarity and
visualization of the fundus. Intraoperative removal
of the corneal epithelium or accidental surgical
trauma to the corneal epithelium results in
postoperative CED, and healing of such lesions
can be delayed, particularly in patients with
diabetes.[2, 7] Postoperative CED is a significant
cause of morbidity in these patients. Virata
et al reported that 45% of such cases of CEDs
persisted for longer than one week and 28%
lasted for four or more weeks. One reported
case resulted in a bacterial corneal ulcer.[8] In
one study, the overall rate of corneal epithelial
debridement during vitrectomy averaged among
55 vitreoretinal surgeons was 17.4% ± 19.0%
and ranged from 0% to 90%,[9] although other
studies reported this rate to be approximately
14–34%.[10, 11] Both structural (polymegathism
and pleomorphism) and functional abnormalities
(increased permeability and slower recovery
from induced edema) are observed in the
diabetic corneal epithelium and endothelium.[12]
EGF,[13–16] FGF, and interlukin-6[17] stimulate
corneal epithelial migration and proliferation.
Fibronectin,[18] hyaluronan,[19] laminin,[20] and
collagen type IV are the extracellular matrix
components that can facilitate epithelial cell
migration. Neuronotrophic substances, such
as substance P, IGF-I, and NGF promote
corneal epithelial migration; topical application
promotes corneal wound healing.[21–25] EGF,
vitamin A, substance P, α2-macroglobulin,
fibronectin, and acidic and basic FGFs are
tear components that play major roles in
proliferation, differentiation, and maturation of
the corneal epithelial cells.[26, 27] Autologous
serum contains factors, such as glucose, proteins,
calcium ion, vitamin A, EGF, fibronectin, and
glycoproteins, that facilitate corneal wound
healing.[28–30] Therefore, autologous serum
eye drops are used to treat ocular surface
disorders.[31]
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Figure 1. Rate of corneal epithelial defect improvement in the topical umbilical cord serum and control groups. CED, corneal
epithelial defect; Cum, cumulative
Table 1. Baseline characteristics of participants
Variable Statistics Groups P-value
Umbilical cord serum (n = 40) Placebo (n = 40)
Age (years) Mean ± SD (Range) 57.6 ± 9.6 (34 to 78) 59.5 ± 11.0 (37 to 80) 0.400†
Sex F/M (F%) 22/55 (55%) 20/20 (50%) 0.654*
Basic CED Size Mean ± SD (Range) 15.3 ± 6.2 (2.3 to 30) 15.7 ± 6.8 (2 to 33) 0.801†
Operation duration (hours) Mean ± SD (Range) 1.65 ± 0.62 (1 to 4) 1.45 ± 0.50 (1 to 2) 0.118∗∗
†Based on t-test; ∗Based on Chi-square test; ∗∗based on Fisher’s exact test. CED, corneal epithelial defect; F, female; M, male;
SD, standard deviation
Table 2. Mean ± standard deviation (range) of the rate of improvement (days)
Operation Groups
Umbilical cord serum (n = 40) Placebo (n = 40) Total Diff (95% CI) P-value (Between)
Vitrectomy 2.4 ± 0.7 (2 to 5) 3.8 ± 2.1 (2 to 12) –1.3 (–2.1 to –0.6) < 0.001†
†Based on t-test
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Table 3. Correlation of age and duration of operation in each group with the rate of improvement of corneal epithelial defects
Groups
Umbilical cord serum (n = 40) Controls (n = 40) Total
Correlation P-value Correlation P-value Correlation P-value
Age 0.205 0.211 –0.004 0.979 0.073 0.522
Operation duration –0.202 0.219 –0.202 0.212 –0.218 0.054
Based on Spearman’s correlation coefficient
Autologous serum eye drops are effective in
cases of keratoconjunctivitis sicca,[32] severe dry
eye,[33, 34] superior limbal keratoconjunctivitis,[35]
persistent CED, and neurotrophic keratopathies.[36]
Higher concentrations of EGF, vitamin A, acidic
and basic FGFs, fibronectin, NGF, substance
P, and α2-macroglobulin, which are present in
UCS, make it more effective than autologous
serum in treating ocular surface disorders.[31]
Recently, Vajpayee et al reported that TUCS
eye drops resulted in faster healing of persis-
tent CED refractory to medical treatments com-
pared to autologous serum drops.[37] Yoon et al
found that the application of TUCS effectively
treated dry eye and persistent CED due to neu-
rotrophic keratitis.[3–5] Autologous serum prepara-
tion requires collection of blood at regular intervals
from patients and may induce discomfort. It is
difficult to obtain blood samples from patients
with a poor general condition or blood dyscra-
sia, but abundant serum can be drawn from
the umbilical vein at once. Many patients can
benefit from this sampling approach, which min-
imizes discomfort.[5] In this study, we examined
the effects of TUCS therapy on improvement of
CED after diabetic vitrectomy. Our study showed
that TUCS hastened the healing of CEDs after
vitrectomy relative to the conventional therapy.
Persistent CED occurred in two cases in the
control group but in no cases in the TUCS
group.
The limitations of our study were the absence
of dry eye tests before surgery and unavail-
ability of precise measurement of CEDs using
Image J or other digital measurement modali-
ties.
In conclusion, TUCS may significantly acceler-
ate the rate of improvement of CEDs after dia-
betic vitrectomy and reduce the risk of persistent
CED. Further studies with larger sample size are
needed.
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